Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Sandy Wong

Sandy Wong

MD

University of California San Francisco

Results from Phase I study of alnuctamab administered intravenously & subcutaneously in R/R myeloma

Results from Phase I study of alnuctamab administered intravenously & subcutaneously in R/R myeloma

Sandy Wong • 25 Jan 2023

Using anti-myeloma agents in amyloidosis

Using anti-myeloma agents in amyloidosis

Sandy Wong • 7 Oct 2022

Evaluating the impact of screening on survival in AL amyloidosis

Evaluating the impact of screening on survival in AL amyloidosis

Sandy Wong • 7 Oct 2022

ALTITUDE: venetoclax, daratumumab, and dexamethasone in systemic AL amyloidosis with t(11;14)

ALTITUDE: venetoclax, daratumumab, and dexamethasone in systemic AL amyloidosis with t(11;14)

Sandy Wong • 7 Oct 2022

Insights into the management of systemic AL amyloidosis

Insights into the management of systemic AL amyloidosis

Sandy Wong • 30 Aug 2022